Mark A. Berman is Chief Medical Officer at Better Therapeutics, Inc. (BTTX). They have made 1 open-market trade across 1 company since 2023, most recently 2023-12-18.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $40K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BTTX | 448,140 | $20K |
Shares reported on the most recent Form 4, priced at the 2023-12-20 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BTTX | BUY | 2023-07-27 | 2023-07-31 | $0.73 | $40K | -7.8% | -19.7% | -79.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.